Remote ischaemic conditioning for stroke: unanswered questions and future directions

Sheharyar Baig,1 Bethany Moyle,1 Krishnan Padmakumari Sivaraman Nair,2 Jessica Redgrave,1 Arshad Majid,3 Ali Ali4,5

ABSTRACT
Remote ischaemic conditioning (RIC) refers to a process whereby periods of intermittent ischaemia, typically via the cyclical application of a blood pressure cuff to a limb at above systolic pressure, confers systemic protection against ischaemia in spatially distinct vascular territories. The mechanisms underlying this have not been characterised fully but have been shown to involve neural, hormonal and systemic inflammatory signalling cascades. Preclinical and early clinical studies have been promising and suggest beneficial effects of RIC in acute ischaemic stroke, symptomatic intracranial stenosis and vascular cognitive impairment. Through systematic searches of several clinical trials databases we identified 48 active clinical trials of RIC in ischaemic stroke, intracerebral haemorrhage and subarachnoid haemorrhage. We summarise the different RIC protocols and outcome measures studied in ongoing clinical trials and highlight which studies are most likely to elucidate the underlying biological mechanisms of RIC and characterise its efficacy in the near future. We discuss the uncertainties of RIC including the optimal frequency and duration of therapy, target patient groups, cost-effectiveness, the confounding impact of medications and the absence of a clinically meaningful biomarker of the conditioning response. With several large clinical trials of RIC expected to report their outcomes within the next 2 years, this review aims to highlight the most important studies and unanswered questions that will need to be addressed before this potentially widely accessible and low-cost intervention can be used in clinical practice.

INTRODUCTION
Remote ischaemic conditioning (RIC) refers to the process by which cycles of temporary ischaemia, typically through the application of a manual or electronic tourniquet to a limb at above systolic blood pressure, confers a systemic protection against future ischaemic injuries in remote vascular territories.1 The concept of ischaemic conditioning as a protective technique was described by Murry et al who found that 5 min cycles of occlusion and reperfusion of canine circumflex arteries repeated 4 times (4×5 mins) prior to experimental myocardial infarction in the same arterial territory led to a 25% reduction in myocardial infarct size compared with controls.2 Subsequently brief episodes of the same ischaemic conditioning protocol applied to the circumflex artery was found to have protective properties when the experimental infarct was induced in a different arterial territory—RIC. It was later discovered that applying similar sublethal episodes of ischaemic to remote organs4 or a limb,5 also offered protection to subsequent ischaemic or reperfusion injury, not only to the heart, but to other organs including liver,6 kidneys7 and brain.8 These findings have led to the investigation of its use in cerebrovascular disease.

The timing of RIC in relation to ischaemia and subsequent reperfusion defines the terms preconditioning (RIPreC), perconditioning (RIPerC) and postconditioning (RIPostC) (Figure 1). The protective effect of ischaemic conditioning occurs at different time frames: the acute effect is induced immediately and lasts 2 hours while the delayed protection occurs at 12–24 hours, lasting upto 48–72 hours.9 Furthermore, repeated cycles of RIC (chronic RIC) may induce distinct adaptations that influence stroke recurrence and recovery.10 11

A small number of studies have investigated the use of RIC in acute and chronic stroke.12–19 and have been summarised in recent review articles.20 21 However, there is a rapidly evolving research landscape with multiple ongoing clinical trials that, when completed and published, will have a significant impact on understanding the utility of RIC in stroke. Here, we outline the ongoing clinical trials investigating RIC in acute and chronic stroke, expand on the key remaining research questions, comprehensively detail the remaining barriers to translation into clinical practice...
and make practice recommendations for future clinical trial design.

METHODS

We searched the following trials registries/journals (25 August 2020) for ongoing or completed trials of RIC in stroke:
1. ClinicalTrials.gov (https://clinicaltrials.gov/).
2. WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/search/en/).
3. ISRCTN Registry (https://www.isrctn.com/).
4. European Union Clinical Trials Register (https://www.clinicaltrialsgen.eu/).
5. BioMedCentral Trials Journal (https://trialsjournal.biomedcentral.com/).
6. Chinese Clinical Trials Registry (www.chictr.org.cn).

Search terms included ‘ischaemic conditioning’ and ‘stroke’. In the Chinese Clinical Trials Registry ‘conditioning’ was used as a search term to widen results. Further studies were identified from previous published articles and citation searches.

Active studies were included if the RIC intervention (cycles of temporary upper or lower limb ischaemia) was being studied in patients with stroke (ischaemic or haemorrhagic stroke), transient ischaemic attack or subarachnoid haemorrhage. Completed studies were included if they met the search criteria above but had not yet published the full results.

Studies were labelled as having an ‘Unknown’ status if: (1) the study status was not available on the relevant clinical trials registry or (2) more than 2 years elapsed since the estimated completion date, without publica-

Figure 1 Model of remote ischaemic conditioning.

and make practice recommendations for future clinical trial design.

Relevant studies

We identified 48 studies investigating RIC in stroke (online supplemental material). After analysing the trial protocols for each study, we determined that the RIC intervention is being studied in three distinct time frames:
1. RIPreC—the administration of RIC prior to a surgical or endovascular procedure where there is a significant risk of stroke.
2. RIPerC and/or early remote ischaemic postconditioning (Early RIPreC) —the administration of RIC in the hours to days after the onset of an acute stroke (ischaemic, haemorrhagic or subarachnoid haemorrhage)
3. Chronic remote RIPreC (Chronic RIC)—the administration of repeated cycles of RIC for weeks to months in patients with a history of stroke.

Table 1 summarises the variety of populations, RIC protocols, outcome measures and estimated completion dates of ongoing clinical trials in RIC. A more detailed summary of individual studies can be found in online supplemental material.

RIPreC: The use of RIPreC is a clinical application of the classic paradigm of ischaemic preconditioning whereby a period of temporary ischaemia induces protective changes which reduce the impact of future sustained ischaemic insults.22 23 While the majority of strokes cannot be predicted, there are several clinical settings in which an ischaemic or haemorrhagic stroke is a potential consequence of a surgical and endovascular procedure, for example, prior to treating cerebral aneurysms,24 carotid endarterectomy and carotid artery stenting.25

Three studies are investigating the potential benefit of RIPreC in reduction of ischaemic stroke or vasospasm after surgical and endovascular treatment of unruptured cerebral aneurysms (NEAT - NCT03496415; RIPAT - NCT0216265426; NCT03814850; online supplemental material).

The largest of these studies (NEAT - NCT03496415), from China, aims to recruit 210 participants from multiple centres, with unruptured intracranial aneurysms, randomising them to bilateral upper limb RIPreC at 200 mm Hg or sham RIPreC at 60 mm Hg prior to neuroendovascular therapies (ET). The primary outcome measure of this study is the presence and volume of new DWI lesions on MRI within 72 hours of ET, while secondary outcomes include day 7 stroke severity (NIHSS score) and cerebrovascular events and modified Rankin Scale (mRS) at 30 days. Importantly, the participant, care provider, investigator and outcomes assessor are all masked to group allocation. The results from this study will indicate whether RIPreC has a potential role as an adjunct for elective aneurysm repair.

The RIPAT study (NCT0216265426) aims to enhance our biomechanistic understanding of the potential benefits of RIPreC before treatment of unruptured aneurysms. This prospective, double-masked explorative trial in Austria, will randomise 48 individuals with asymptomatic intracranial aneurysms to RIPreC (3×5 min cycles in the upper arm at 200 mm Hg) or sham RIPreC (3×5 min cycles in the upper arm at 10 mm Hg), while measuring inflammatory cytokines associated with the conditioning response (S100 calcium-binding protein B (S100B),
Table 1  Summary characteristics of ongoing trials of RIC in stroke

| Parameter                  | No of studies |
|---------------------------|---------------|
| Study population          |               |
| Ischaemic stroke/TIA      | 31            |
| Symptomatic intracranial stenosis | 8         |
| Aneurysmal subarachnoid haemorrhage | 4        |
| Unruptured cerebral aneurysm | 3             |
| Intracerebral haemorrhage | 3             |
| Timing of conditioning    |               |
| RIPreC                    | 3             |
| RIPerC and early RIPostC  | 28            |
| Chronic RIPostC           | 16            |
| Unspecified               | 1             |
| Participants (N)          |               |
| <100                      | 24            |
| 100–500                   | 17            |
| 501–1000                  | 4             |
| >1000                     | 3             |
| RIC protocol              |               |
| Cuff pressure             |               |
| 180 mm Hg                 | 2             |
| 200 mm Hg                 | 26            |
| 225 mm Hg                 | 2             |
| 20 mm Hg >SBP             | 4             |
| 30 mm Hg >SBP             | 2             |
| 50 mm Hg >SBP             | 1             |
| 110 mm Hg >SBP            | 1             |
| Variable                  | 1             |
| Unspecified               | 9             |
| Cycle length              |               |
| 3 min                     | 1             |
| 5 min                     | 36            |
| 10 min                    | 1             |
| Variable                  | 1             |
| Unspecified               | 9             |
| Cycle frequency           |               |
| 3                         | 5             |
| 4                         | 16            |
| 5                         | 19            |
| Variable                  | 1             |
| Unspecified               | 7             |
| Limb                      |               |
| Upper                     | 36            |
| Lower                     | 5             |
| Unspecified               | 7             |
| Unilateral                | 18            |
| Bilateral                 | 16            |
| Unspecified               | 14            |
| Study location            |               |
| Asia                      | 30            |
| Europe                    | 10            |
| North America             | 8             |
| Primary outcome measures  |               |
| Clinical                  |               |
| modified Rankin Scale     | 6             |
| Compliance/feasibility    | 6             |
| Adverse events            | 6             |
| Recurrent stroke          | 4             |
| Combined vascular events  | 1             |

Continued
Matrix Metallopeptidase 9 (MMP 9), Glial Fibrillar Acidic Protein (GFAP), Myelin Basic Protein, Neuron-Specific Enolase). Ischaemic lesions (number and volume) will be measured by DWI MRI at 12–48 hours post-treatment, with clinical outcomes (NIHSS and mRS) and neuropsychological testing measured at 6 and 12 months. A caveat to this study is that two different procedures (endovascular coiling and surgical clipping) are being used which may bias results. The current status of this trial is unknown, however, the results are of significant interest in developing our understanding of the temporal nature of the inflammatory cascade that follows RIPreC and assessing its potential impact on the development of periprocedural ischaemia.

RIPerC and early RIPostC

We identified 28 studies investigating RIPerC and early RIPostC as an adjunct to hyperacute stroke care (online supplemental material). Putative beneficial mechanisms of RIC in this hyperacute setting include increased cerebral blood flow (CBF) and perfusion of the ischaemic penumbra.27 The primary aims for many of these studies are to establish whether RIPerC and/or early RIPostC is safe and can reduce stroke severity assessed by clinical and radiological indicators. Alongside this, several studies are investigating the feasibility of hyperacute RIC alongside intravenous thrombolysis (SERIC-TAIS - NCT04027621; rTPA-RIC - NCT02886390; rTPA-RIC1 - NCT0321384; TRIPCAIS - NCT03218293) and ET (PROTECT-I - NCT03915782; REVISE-2 - NCT03045055; RICE-PAC - NCT03152799). While the most trials are investigating whether RIC in ischaemic stroke, a subset of studies are investigating RIC in intracerebral haemorrhage and subarachnoid haemorrhage (online supplemental material).

The largest study of RIC in acute stroke in Europe, the Danish RESIST trial (NCT03481777) will randomise 1500 participants (baseline mRS ≤ 2) presenting within 4 hours of symptom onset with a prehospital putative stroke (combined Cincinattti Prehospital Stroke Scale and Postural Assessment Scale for Stroke) to RIPerC/sham in the prehospital phase and RIPostC/sham after 6 hours in confirmed cases of acute ischaemic or haemorrhagic stroke. The active arm involves 5×5 min cycles of unilateral upper arm occlusion at 200 mm Hg (or 35 mm Hg above SBP if baseline SBP is >175 mm Hg) while sham occlusion pressure rests at 20 mm Hg. The primary outcome measure of 3 month mRS will be supplemented with composite cardiovascular event rates at 3 months and 1 year, as well as quality of life measures and hospital bed-day use. Participants at the central site will also be randomised to RIPostC or sham RIPosC twice daily for 7 days to facilitate an assessment of the incremental effect of repeated doses of RIC. In a subset of patients, the investigators will also assess the impact of RIC on DWI infarct growth at 24 hours (in ischaemic stroke)
and haematomata expansion on CT (in haemorrhagic stroke).

Other studies, such as RICAMIS (NCT03740971; 1800 participants) and SERIC-AIS in China (NCT03669653; 912 participants), REMOTE-CAT in Spain (NCT03375762; 572 participants) and RESCUE-Brain in France (NCT02189928; 200 participants), will be of significant value in determining the relative efficacy of RIC in hyperacute stroke in different populations. However, there are important methodological differences in the study populations, inclusion criteria, timing and duration of RIC, and endpoints that may preclude the reliability of any future meta-analysis. The key differences between the large trials of RIC in acute stroke are summarised in table 2.

**Chronic RIC**

We identified 16 studies investigating the use of chronic RIC in patients with stroke (online supplemental material), a large proportion of which concentrate on the secondary preventative effect in symptomatic intracranial atherosclerosis. However, a number of trials (once daily vs twice daily) on stroke recurrence. At the same centre, ChiCTR1800014403 will randomise 273 individuals with symptomatic intracranial stenosis to either 3x3 mins or 5x5 mins cycles of RIC twice daily and compare the effect of a shorter RIC intervention on secondary prevention. Timing of RIC in Acute Stroke: The optimal timing of RIC delivery in acute stroke is unclear. Among the major trials of RIC in acute stroke there is significant heterogeneity in patient inclusion criteria and the timing of RIC (table 2). For instance, in RICAMIS (NCT03740971) only acute moderate-severe ischaemic stroke (National Institute of Health Stroke Scale, NIHSS 6–16) cases confirmed on neuroimaging and within 48 hours of symptom onset are included while, in the REST study (NCT03481777), RIC is commenced in a prehospital phase for patients with a presumed stroke (based on the combined Cincinnati Prehospital Stroke Scale and Postural Assessment Scale for Stroke) within 4 hours of symptom onset. A schematic of the timing and duration of RIC in the larger acute stroke trials is illustrated in figure 2. If the beneficial effects of RIC in acute stroke require early intervention, then adequately powered studies of RIC delivered in the prehospital phase are essential to establish its efficacy.

Duration: It remains unclear whether there is a ceiling effect of repeated, daily RIC; if RIC is still efficacious when delivered on a less frequent basis, this may increase uptake and concordance. In chronic stroke, RIC has been used daily for up to 300 days. Meng et al reported on a proof-of-concept study of twice daily bilateral upper limb RIC for 300 days in patients with symptomatic intracranial stenosis. Those in the treated arm (n=38) experienced significant reductions in stroke recurrence after 90 and 300 days of RIC compared with controls treated with medical therapy alone (n=30). The Kaplan-Meier analysis of stroke recurrence indicates deviation of RIC group from controls after around 60 consecutive days of RIC, however, it is unclear whether a shorter duration of chronic RIC (eg, 60 days) would be sufficient to

**Method of delivery**

**Dose and frequency**

The minimally effective and most effective dose and frequency of RIC is unclear. With most studies employing between 3–5 × 5 minute cycles of upper limb ischaemia at 200 mm Hg once daily, a single ‘dose’ of RIC can last between 30 and 50 mins. Table 1 illustrates the variation in RIC protocols used in ongoing clinical trials. By identifying the dose–response relationship between RIC and any potential clinical benefits clinicians will be better able to counsel patients with shorter cycle lengths potentially resulting in improved concordance with therapy.

In addition to the REST trial, investigating single and repeated RIC in acute stroke, two further studies are investigating the optimal dose and frequency of chronic RIC (NCT03105141 and ChiCTR1800014403). In the first study, NCT03105141, 600 patients with symptomatic intracranial stenosis and a recent stroke or high-risk TIA are stratified into 1 of 10 treatment groups. All the treatment groups receive automated RIC daily for 1 year with substudies assessing the effect of different cuff pressures (200 mm Hg or 40 mm Hg above systolic), cycle length (4.5 or 6 mins), cycle number (4, 5 or 6) and frequency (once daily vs twice daily) on stroke recurrence. At the same centre, ChiCTR1800014403 will randomise 273 individuals with symptomatic intracranial stenosis to either 3x3 mins or 5x5 mins cycles of RIC twice daily and compare the effect of a shorter RIC intervention on secondary prevention. Timing of RIC in Acute Stroke: The optimal timing of RIC delivery in acute stroke is unclear. Among the major trials of RIC in acute stroke there is significant heterogeneity in patient inclusion criteria and the timing of RIC (table 2). For instance, in RICAMIS (NCT03740971) only acute moderate-severe ischaemic stroke (National Institute of Health Stroke Scale, NIHSS 6–16) cases confirmed on neuroimaging and within 48 hours of symptom onset are included while, in the REST study (NCT03481777), RIC is commenced in a prehospital phase for patients with a presumed stroke (based on the combined Cincinnati Prehospital Stroke Scale and Postural Assessment Scale for Stroke) within 4 hours of symptom onset. A schematic of the timing and duration of RIC in the larger acute stroke trials is illustrated in figure 2. If the beneficial effects of RIC in acute stroke require early intervention, then adequately powered studies of RIC delivered in the prehospital phase are essential to establish its efficacy.

Duration: It remains unclear whether there is a ceiling effect of repeated, daily RIC; if RIC is still efficacious when delivered on a less frequent basis, this may increase uptake and concordance. In chronic stroke, RIC has been used daily for up to 300 days. Meng et al reported on a proof-of-concept study of twice daily bilateral upper limb RIC for 300 days in patients with symptomatic intracranial stenosis. Those in the treated arm (n=38) experienced significant reductions in stroke recurrence after 90 and 300 days of RIC compared with controls treated with medical therapy alone (n=30). The Kaplan-Meier analysis of stroke recurrence indicates deviation of RIC group from controls after around 60 consecutive days of RIC, however, it is unclear whether a shorter duration of chronic RIC (eg, 60 days) would be sufficient to...
Table 2: Summary of the major clinical trials of RIPerC and early RIPostC in acute stroke

| Study              | N   | Population and timing                                                                 | RIC protocol and duration | Control group       | Primary outcome measure | Selected secondary outcome measures                                                                 |
|--------------------|-----|---------------------------------------------------------------------------------------|---------------------------|----------------------|-------------------------|------------------------------------------------------------------------------------------------------|
| RICAMIS (NCT03740971) China 2018–2020 | 1800 | Acute moderate ischaemic stroke (NIHSS 6–16), confirmed on CT/MRI, and within 48 hours of symptom onset | 5×5 mins (200 mm Hg) Bilateral UL Twice daily 10–14 days | Usual care | mRS at day 90 | NIHSS day 12 Stroke associated pneumonia All-cause mortality day 90 Biomarkers (BDNF, VEGF, HIF-1α, TNF-α, IL-1β, IL-6) |
| RESIST (NCT03481777) Denmark 2018–24 | 1500 | Acute ischaemic stroke and acute intracerebral haemorrhage, Prehospital Stroke Score ≥1* and within 4 hours of symptom onset. RIC commenced at prehospital phase with further cycles if confirmed stroke. | 5×5 mins (200 mm Hg) Unilateral UL Twice daily Up to 7 days | Sham RIC at 20 mm Hg | mRS at day 90 | Prehospital stroke score at 24 hours. All-cause mortality at 1 year Biomarkers: nitric oxide synthase phosphorylation, microRNA and extracellular vesicle profile |
| SERIC-AIS (NCT03669653) China 2018–22 | 912  | Clinical diagnosis of acute ischaemic stroke (NIHSS 5–25) and within 12 hours of symptom onset. | 4×5 mins (200 mm Hg) UL Twice daily Up to 7 days | Sham RIC (60 mm Hg) | mRS day 90 | NIHSS day 7 Inflammatory cytokines |
| REMOTE-CAT (NCT03375762) Spain 2019–22 | 572  | Suspected clinical stroke (RACE scale >0 and RACE motor item >0) and within 8 hours of symptom onset. | 5×5 mins Unspecified cuff pressure Non-paretic UL | Sham RIC (unspecified pressure) | mRS day 90 | NIHSS day 5 Infarct volume (DWI MRI) Metabolomic and lipidomic biomarkers |
| REPOST (NTR6880) Netherlands 2018–2019 | 200  | Clinical diagnosis of ischaemic stroke and within 12 hours of symptom onset. | 4×5 mins (20 mm Hg >SBP) Unilateral UL Twice daily Up to 4 days | Sham RIC at 50 mm Hg | Infarct size on DWI MRI at day 4/day of discharge if earlier | mRS at 12 weeks NIHSS at discharge SSQoL and TOPICS-SF at 12 weeks and 1-year serum biomarkers |
| RESCUE BRAIN (NCT02189928) France 2015–2019 | 200  | Acute ischaemic stroke (NIHSS 5–25), confirmed on MRI and within 6 hours of symptom onset | 4×5 mins (110 mm Hg >SBP) Unilateral LL Single treatment | Usual Care | Infarct growth on DWI MRI at 24 hours | NIHSS day 1 mRS and Barthel Index at 12 months Recanalisation rates after thrombolysis/thrombectomy |

*The Prehospital Stroke Score is a combined score of the Cincinnati Prehospital Stroke Scale and Postural Assessment Scale for Stroke mRS. BDNF, Brain-derived Neurtrophilic Factor; DWI, Diffusion Weighted Imaging; HIF-1α, Hypoxia-inducible Factor 1-alpha; IL-6, interleukin 6; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; RACE, Rapid Arterial Occlusion Evaluation; RIC, remote ischaemic conditioning; SBP, systolic blood pressure; SSQoL, Stroke Specific Quality of Life Scale; SSQoL, Stroke Specific Quality of Life ; TNFα, tumour necrosis factor-α; TOPICS-SF, The Older Persons and Informal Caregivers Short Form; TOPICS-SF, The Older Persons and Informal Caregivers Survey Short Form; VEGF, Vascular Endothelial Growth Factor.
sustain a clinically beneficial effect over the long term. The maximum follow-up time in current RIC studies is 12 months, which may be suboptimal given the follow-up times required to prove effectiveness in secondary prevention trials of antiplatelets and statins. Taken together, this could help establish an agreed protocol of either a single course of RIC, periodic RIC or lifelong RIC. Both the use of RIC for stroke prevention, potentially lifelong, and long term trial follow-up, are significant investments for patients and trialists, respectively. The discovery of validated biomarkers for vascular protection could shorten follow-up times and identify patients responding to treatment, negating the need for unnecessary long term treatment.

Unilateral versus bilateral RIC
While bilateral RIC may theoretically produce a larger ischaemic stimulus, no study is currently comparing the clinical impact of unilateral vs bilateral RIC. Unilateral RIC may be more convenient for individuals with hemiparesis and may allow concurrent completion of daily tasks during therapy. Furthermore, in the context of hyperacute stroke, the use of unilateral RIC enables the other arm to be used for venous access and intravenous thrombolysis.

For unilateral RIC, it is unclear if the marginal gain from repeated conditioning in the same limb diminishes over time. As such, it would be helpful to establish whether alternating the site of delivery has a role in maintaining the conditioning stimulus over time. Furthermore, it is unclear whether the use of unilateral RIC in the paretic arm yields the same conditioning response as RIC in the non-paretic arm; experimentally, nerve transection has been shown to block the effect of preconditioning, however, this has not been established for organic central lesions.

Upper limb versus lower limb RIC
While lower limb RIC has the theoretical potential to induce a larger ischaemic stimulus, a study of RIC in healthy volunteers showed no significant differences in the production of nitrite, a potential signalling mediator of the conditioning response, after upper limb or lower limb RIC in healthy volunteers. However, as discussed, given the conditioning response likely involves multiple signalling cascades that occur over different time frames, there is insufficient evidence to conclude that upper limb and lower limb RIC are equipotent. We found only five studies investigating lower limb RIC (RESCUE-BRAIN (NCT02189928), PreLIMBS (NCT02411266), RIPC-SAH (NCT02981522), NCT04039399, NCT04038697). The preponderance of interventions using upper limb RIC may reflect increased practicality for both patients and carers. A qualitative analysis of patient experience with both upper and lower limb RIC may reveal key barriers to longer-term compliance that can help investigators optimise intervention strategies.

Safety and tolerability
Multiple clinical trials suggest that RIC is safe, even when performed twice daily on both arms for 300 days, including in the elderly. However, relatively few studies of chronic RIC have reported on compliance, therefore, it is difficult to ascertain whether stroke patients are able to carry out RIC for sustained periods of time. In Meng et al., 51 patients with symptomatic intracranial stenosis were randomised to receive twice daily bilateral arm conditioning for 300 consecutive days but only 38 (74.5%) completed the study. Long-term data on larger cohorts will help inform clinicians on likely compliance rates.

A small number of side effects have been reported including skin petechiae, but no studies have indicated increased risks of venous thrombosis or rhabdomyolysis. It is unclear if chronic RIC affects sensory or motor function of the conditioned limbs; studies that include these detailed clinical and electrophysiological assessments as outcome measures should help fill this knowledge gap.

A consistent exclusion criterion for several clinical trials of RIC in stroke has been known peripheral vascular disease or venous thromboembolism affecting the conditioned limb. While there is a theoretical risk of harm in these patients, the fact that prior studies have not highlighted incident risk of these complications, and that studies are investigating upper limb RIC in patients with known lower limb peripheral arterial disease, should provide some reassurance to clinicians.

RIC and ET
The usefulness of RIC alongside ET for large vessel occlusion (LVO) has attracted much research interest. Numerous questions arise. The first is whether RIC can be delivered parallel to ET without causing significant treatment delays. The second is whether, RIC performed alongside recanalisation of a culprit vessel may influence cerebral autoregulation in a manner that increases the risk of reperfusion injury or haemorrhagic transformation. Hypertension and impaired cerebral autoregulation
often already accompany acute ischaemic stroke. The third is whether the effect of general anaesthetic diminishes the effect of RIC; as previous studies have indicated, the use of propofol inhibits the ischaemic conditioning response.

Manual versus automated RIC
Automated RIC devices are widely available. While RIC has been marketed as a potentially low-cost, non-invasive intervention for vascular diseases, the costs of obtaining multiple devices, cuff and battery replacements, may prove to be prohibitively expensive in low and middle income countries where the rates of cerebrovascular disease remain high. As such, studies which deploy manual RIC (with sphygmomanometers and digital timers) will help develop the global translatability of RIC.

Three studies plan to compare the effect of RIC in those undergoing ET (REVISE-2 - NCT03045055, PROTECTI - NCT03915782, RICE-PAC - NCT03152799) (online supplemental material). As well as revealing efficacy, these will highlight the practical challenges of delivering RIC to patients in a time-sensitive manner.

Target populations
Intracranial stenosis: The majority of studies of chronic RIC have been performed in individuals with significant intracranial stenosis. This is an important population to study for two reasons: high stroke recurrence rates in this population mean a lower sample size is needed to detect a significant treatment effects, and they are a subgroup where significant improvements in care can potentially be made. However, while intracranial atherosclerosis contributes to ischaemic stroke in a large proportion of individuals globally, it is a less common mechanism of stroke in European and North American populations where extracranial carotid disease, cardioembolic stroke and small vessel disease are more common. As such, studies need to extend to individuals without intracranial stenosis to establish the utility of RIC in the wider setting of secondary stroke prevention. Furthermore, most studies of chronic RIC in ischaemic stroke have been performed in East Asia; while there is no identifiable reason why the response to RIC would be different in a different population, it is important for similar studies to be undertaken outside of Asia to identify whether the chronic RIC is both tolerated and beneficial in a wider global setting.

The influence of comorbidities and medications: It is recognised that the impact of RIC may diminish with age. However, Meng et al. demonstrated that RIC may reduce stroke recurrence in those over 80 thereby suggesting that ageing alone may not suppress the beneficial effects of RIC.

Diabetes mellitus is a common risk factor for ischaemic stroke, however, evidence from both animal models and clinical studies suggest that diabetes, particularly diabetic neuropathy, may abolish the protective effect of RIC. For instance, a recent study of chronic, daily RIC in patients with diabetes with peripheral arterial disease failed to show any positive impact on vascular or neuronal function; potentially linked to impairment of the neurogenic pathways thought to potentiate the action of RIC. The theoretical risk of compounding nerve damage with repeated limb compression in chronic RIC may also be a reason for excluding such patients from trials, and their ultimate under-representation in the literature. Subgroup analyses of larger randomised controlled trials or pooled datasets may help determine if the presence of diabetes truly impacts on the clinical effects of RIC.

Animal models also suggest that the conditioning response is diminished by the presence of comorbidities such as hypercholesterolaemia, hypertension and obesity. However, this has not yet been confirmed in clinical studies of RIC in stroke. Similarly, several medications that are commonly prescribed in individuals with cardiovascular disease including nitrates, atorvastatin and nicorandil may activate similar intracellular signalling cascades to RIC. However, clinical data are lacking with respect to understanding whether this would potentiate or abrogate the effects of RIC in patients taking these medications.

Cardioembolic stroke
Studies of RIC in ischaemic stroke typically exclude individuals with known cardioembolism from causes such as atrial fibrillation or flutter. In these patients, stroke often results from the sudden migration of thrombus from the heart to the cerebral arteries, a pathway that RIC may not obviously affect at first glance. However, the impact of RIC on secondary prevention of cardioembolic stroke is of interest for several reasons. First, the seminal studies investigating the protective effect of ischaemic preconditioning were performed in animal models where ischaemia was precipitated acutely, a mode of infarction more akin to cardio-embolism than atherosclerotic disease. It may be that slow atheromatous progression and intracranial stenosis leads to a degree of endogenous pre-conditioning that reduces the marginal impact of RIC compared with those with cardio-embolic stroke. Consistent with this, previous studies have indicated that the volume of ischaemia resulting from cardioembolism is larger than that due to a similar sized clot from the carotid/intracranial circulation. Furthermore, the most common cause of cardio-embolism, atrial fibrillation, develops predominantly in later life and in the context of cardiovascular risk factors such as hypertension and diabetes mellitus. As such, many patients with atrial fibrillation have associated endothelial dysfunction, another pathway potentially impacted by RIC.

Small vessel ischaemic disease
Small vessel ischaemic disease (SVID) is a common comorbidity and complication associated with stroke and is a precursor for the development of vascular cognitive impairment (VCI) and vascular dementia. The role of RIC in SVID has attracted interest due its potential effects on
CBF and inflammatory markers. In SVID, hypoperfusion due to microangiopathy can precipitate neurodegeneration through disruption of the blood–brain barrier and neuroinflammation. Declines in cognitive function have also been associated with reduced microvascular perfusion. Small pilot studies of patients with established SVID or those with VCI have shown that RIC applied twice daily (5×5 min cycles) for between 6 and 12 months can result in improvements in CBF velocities, reductions volume of white matter lesions, and variable improvements in domains of cognitive function. Investigations are currently under way to evaluate whether once daily application, for a shorter duration of 1 month has similar effects with greater treatment adherence.

RIC and exercise
Experimental and clinical evidence suggests shared biological mechanisms for the effects of RIC and exercise, including increased heat shock proteins and increased endothelial nitric oxide signalling. It is unclear whether there is any synergistic effect of RIC when performed in addition to regular exercise, and no current studies evaluating this in chronic stroke. While exercise confers many physiological benefits in stroke patients, numerous barriers to exercise poststroke exist including depression, fatigue and physical disability. As such, if there are physiological effects of RIC that mirror exercise, then this may be a useful long-term ancillary treatment when patients are physically unable to exercise.

Underlying mechanism and biomarkers
Applying an external pressure to occlude blood flow to a limb initiates transmission of a signal that mediates the RIC response. Humoral, neurogenic and immune mediated pathways have been proposed as transmission and end organ effector mechanisms. After the transmission of the conditioning stimulus, an array of possible biochemical and physiological changes may contribute to clinically meaningful outcomes in stroke patients including increased CBF, angiogenesis and increased collateral circulation, antiplatelet effects, immune regulation, mitochondrial function and autophagy regulation. (figure 3). The latency of these biological mediators and effectors may vary and are likely to underpin differences in effects of acute and chronic RIC. Establishing the underlying mechanisms and final effectors of RIC will prove essential in optimising intervention development, trial design and establishing its efficacy and safety in wider clinical practice. Furthermore, by characterising the intracellular pathways associated with the beneficial effects of RIC, appropriate drug targets may be identified, leading the way towards pharmacological conditioning.

For subarachnoid haemorrhage, the putative biological mechanism for any potential benefit of RIC are not well characterised but may involve reducing vasospasm. In intracerebral haemorrhage, there are pathophysiological consequences that are shared with ischaemic stroke including endothelial dysfunction, impaired cerebral autoregulation, a proinflammatory milieu and mitochondrial dysfunction; these have all been proposed as therapeutic targets of RIC in ischaemic stroke, and therefore, may prove to be of significance in intracerebral haemorrhage.

Circulating biomarkers
Previous studies have indicated potential serum signalling mediators of RIC including heat shock proteins, tumor necrosis factor (TNF)-α and interleukin 6 (IL-6). However, no established circulating biomarkers have been shown to be reliably correlate with the degree of conditioning response or clinical outcomes. Identifying a serum biomarker would be advantageous as it could offer a minimally invasive measure to: (1) establish which patients are responding to the treatment and (2) optimise the dose, frequency and duration of RIC treatment on an individualised basis. Several ongoing studies are investigating candidate circulating biomarkers including...
RIC has been shown to be a promising therapy in animal models of stroke while smaller clinical studies have indicated its safety and feasibility in humans. However, there are several remaining questions before results of these studies can be translated into widespread clinical practice. Ongoing clinical trials will inform whether RIC is effective in the acute and chronic setting of stroke. However, there is an urgent need to concurrently investigate which patient groups respond best to RIC, identify the optimal dose and duration of therapy, and to establish biological and radiological biomarkers of the conditioning response before RIC can advance into routine clinical practice.

CONCLUSIONS

Several studies investigating chronic RIC are measuring cerebral and skeletal muscle blood flow using a range of modalities including TCD, Arterial Spin Labelling and MR angiography (NCT03635177, NCT02323425 and NCT04038697). If increased cerebral or skeletal muscle blood flow is associated with positive clinical outcomes in the larger studies of chronic RIC then non-invasive assessments of blood flow could be used to establish response to RIC on a personalised level.

Economic analysis

The costs of automated conditioning devices, device maintenance and safety monitoring need to be factored into a cost-benefit analysis of RIC in stroke. Furthermore, additional care staff may be required to administer RIC to individuals who are unable to independently apply the device.

Recommendations for future trial design

Given the multitude of ongoing studies for RIC in stroke, a collaborative effort is required to synthesise the array of results into meaningful outcomes for stroke patients. Figure 4 represents a proposed schema for future clinical trial design, identifying six key areas which future studies should focus their attention in order to address the remaining uncertainties of RIC in stroke.

CONCLUSIONS

RIC has been shown to be a promising therapy in animal models of stroke while smaller clinical studies have indicated its safety and feasibility in humans. However, there are several remaining questions before results of these studies can be translated into widespread clinical practice. Ongoing clinical trials will inform whether RIC is effective in the acute and chronic setting of stroke. However, there is an urgent need to concurrently investigate which patient groups respond best to RIC, identify the optimal dose and duration of therapy, and to establish biological and radiological biomarkers of the conditioning response before RIC can advance into routine clinical practice.
REFERENCES

1. Heusch G, Botker HE, Przyklenk K, et al. Remote ischemic conditioning. J Am Coll Cardiol 2015;65:177–95.
2. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:124–36.
3. Przyklenk K, Bauer B, Ovize M, et al. Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 1993;87:893–9.
4. Gho BC, Schoemaker RG, van den Doel MA, et al. Myocardial protection by brief ischemia in noncardiac tissue. Circulation 1996;94:2193–200.
5. Jensen HA, Loukogeorgakis S, Yannopoulos F, et al. Remote ischemic preconditioning protects the brain against injury after hypothermic circulatory arrest. Circulation 2011;123:714–21.
6. Tapuria N, Kumar Y, Habib MM, et al. Remote ischemic preconditioning: a novel protective method from ischemia reperfusion injury—a review. J Surg Res 2008;150:304–30.
7. Wever KE, Warle MC, Wagener FA, et al. Remote ischemic preconditioning by brief hind limb ischemia protects against renal ischaeemia-reperfusion injury: the role of adenosine. Nephrol Dial Transplant 2011;26:3108–17.
8. Candiloli L, Malik A, Hausenloy DJ. Protection of organs other than the heart by remote ischemic conditioning. J Cardiovasc Med 2013;14:193–205.
9. Zhou G, Li MH, Tudor G, et al. Remote ischemic preconditioning in cerebral diseases and neurointerventional procedures: recent research progress. Front Neurol 2019;8:339.
10. Doepchner TR, Zechmeister B, Kaltwasser B, et al. Remote ischemic preconditioning induces sustained neurological recovery by mechanisms involving enhanced angiogenesis and peripheral immunosuppression reversal. Front Cell Neurosci 2018;12:383.
11. Khan MB, Hafez S, Hoda MN, et al. Chronic remote ischemic conditioning is cerebroprotective and induces vascular remodeling in a VCD model. Transl Stroke Res 2019;10:9:51–63.
12. Durand MJ, Boerger TF, Nguyen JN, et al. Two weeks of ischemic preconditioning improves walking speed and reduces neuromuscular fatigability in chronic stroke survivors. J Appl Physiol 2019;126:755–63.
13. England TJ, Hedstrom A, O’Sullivan S, et al. RECAST (remote ischemic conditioning after stroke trial): a pilot randomized placebo controlled phase II trial in acute ischemic stroke. Stroke 2017;48:1412–16.
14. Hougaard KD, Hjort N, Zeidler D, et al. Remote ischemic preconditioning as an adjunct therapy to thrombolysis in patients with acute ischemic stroke: a randomized trial. Stroke 2014;45:159–67.
15. Meng R, Asmoro K, Meng L, et al. Upper limb ischemic preconditioning prevents recurrent stroke in intracranial arterial stenosis. Neurology 2012;79:1853–61.
16. Meng R, Ding Y, Asmoro K, et al. Ischemic conditioning is safe and effective for octo- and nonagenarians in stroke prevention and treatment. Neurotherapeutics 2015;12:667–77.
17. Zhao W, Che R, Li S, et al. Remote ischemic conditioning for acute stroke patients treated with thrombectomy. Ann Clin Transl Neurol 2018;5:850–6.
18. Zhao W, Meng R, Ma C, et al. Safety and efficacy of remote ischemic preconditioning in patients with severe carotid artery stenosis before carotid artery stenting: a proof-of-concept, randomized controlled trial. Circulation 2017;135:1325–+.
19. England TJ, Hedstrom A, O’Sullivan SE, et al. Remote ischemic conditioning after stroke trial 2: a phase IIb randomized controlled trial in hyperacute stroke. J Am Heart Assoc 2019;8:e013572.
20. Landman TRJ, Schoon Y, Warle MC, et al. Remote ischemic conditioning as an additional treatment for acute ischemic stroke the preclinical and clinical evidence. Stroke 2019;50:1934–9.
21. Zhao W, Li S, Ren G, et al. Remote ischemic conditioning for stroke: clinical data, challenges, and future directions. Ann Clin Transl Neurol 2019;6:186–96.
22. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:124–36.
23. Przyklenk K, Bauer B, Ovize M, et al. Regional ischemic ‘preconditioning’ protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 1993;87:993–9.
24. Birinjik W, Murad MH, Lanzino G, et al. Endovascular treatment of intracranial aneurysms with flow diverters: a meta-analysis. Stroke 2013;44:442–7.
25. Muller MD, von Selten S, Algra A, et al. Immediate and delayed procedural stroke or death in stenting versus endarterectomy for symptomatic carotid stenosis. J Vasc Surg 2019;69:968–9.
26. Tüll S, Mulin M, Pinggera D, et al. Remote ischemic preconditioning in the prevention of ischemic brain damage during intracranial aneurysm treatment (RIPAT): study protocol for a randomized controlled trial. Trials 2015;16:594.
27. Kitagawa K, Saitoh M, Ishizuka K, et al. Remote limb ischemic conditioning during cerebral ischemia reduces infarct size through enhanced collateral circulation in murine focal cerebral ischemia. J Stroke Cerebrovasc Dis 2018;27:831–8.
28. Ye Y-D, Guo Z-N, Qin C, et al. Remote ischemic conditioning combined with intravascular thrombolysis for acute ischemic stroke. Ann Clin Transl Neurol 2020;7:972–9.
29. Zhang F, Resta C, Messerer EE, et al. A multicenter, randomized trial on neuroprotection with remote iSchemic per-conditioning during acute iSchemic stroke: the remote iSchemic conditioning in acute brain infarction protocol. Int J Stroke 2016;11:938–43.
30. Hou C, Duan J, Luo Y, et al. Remote limb ischemic preconditioning for intracranial atherosclerotic stenosis patients. Int J Stroke 2016;11:831–8.
31. Sacco RL, Diener H-C, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008;359:1298–303.
32. Halkes PHA, van Gijn J, et al. ESPRIT Study Group, Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006;367:1655–63.
33. Steenstra T, Li-J, Dai X, et al. Pretreatment with the nitric oxide donor SNAP or nerve transaction blocks humoral preconditioning by remote limb ischemia or intra-arterial adenosine. Am J Physiol Heart Circ Physiol 2010;299:H1598–603.
34. Dezfulian C, Taft M, Corey C, et al. Biochemical signaling by remote ischemic conditioning of the arm versus thigh: is one raise of the cuff enough? Redox Biol 2017;12:491–8.
35. Hansen CS, Jørgensen ME, Fleischer J, et al. Efficacy of long-term remote ischemic conditioning on vascular and neuronal function in type 2 diabetes patients with peripheral arterial disease. J Am Heart Assoc 2019;8:e011775.
36. Chi N-F, Hu H-H, Wang C-Y, et al. Dynamic cerebral autoregulation is an independent functional outcome predictor of mild acute ischemic stroke. Stroke 2018;49:2605–11.
37. Guo Z-N, Guo W-F, Liu J, et al. Changes in cerebral autoregulation and blood biomarkers after remote ischemic preconditioning. Neurology 2019;93:e8–19.
38. Kottenberg E, Thielmann M, Bergmann L, et al. Protection by remote ischemic preconditioning during coronary artery bypass graft surgery with isoflurane but not propofol - a clinical trial. Acta Anaesthesiol Scand 2012;56:30–8.
39. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of stroke during 1990-2010: findings from the global burden of disease study 2010. Lancet 2014;383:245–55.
40. Kolominsky-Rabas PL, Weber M, Gefeller O, et al. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke 2001;32:2735–40.
41. White H, Boden-Alba B, Wang C, et al. Ischemic stroke subtype incidence among whites, blacks, and Hispanics; the Northern Manhattan study. Circulation 2005;111:1327–31.
42. McCafferty K, Forbes S, Thiemermann C, et al. The challenge of translating ischemic conditioning from animal models to humans: the role of comorbidities. Dis Model Mech 2014;7:1321–32.
43. Tsagi S, Singh N, Virdi JK, et al. Diabetes abolish cardioprotective effects of remote ischemic conditioning: evidences and possible mechanisms. J Physiol Biochem 2019;75:19–28.
44. Sivaraman V, Yellon DM. Pharmacologic therapy that simulates conditioning for cardiac ischemic/reperfusion injury. J Cardiovasc Pharmacol Ther 2014;19:83–96.
45. Wei M, Kallenberg K, Berg A, et al. Attenuated stroke severity after produral TIA: a role for ischemic tolerance in the brain? Stroke 1999;30:1851–4.
46. Szuzi M, Arena R. Endothelial dysfunction and pathophysiological correlates in atrial fibrillation. Heart 2009;95:102–6.
47. You J, Feng L, Bao L, et al. Potential applications of remote limb ischemic conditioning for chronic cerebral circulation insufficiency. Front Neurol 2019;10:467.
48. Malajovic S, Giannakopoulos P, Sorensd FA, et al. Ultrasound and dynamic functional imaging in vascular cognitive impairment and Alzheimer’s disease. BMC Med 2017;15:27.
Zhang CE, Wong SM, Uiterwijk R, et al. Intravoxel incoherent motion imaging in small vessel disease: microstructural integrity and microvascular perfusion related to cognition. Stroke 2017;48:658–63.

Mi T, Yu F, Ji X, et al. The interventional effect of remote ischemic preconditioning on cerebral small vessel disease: a pilot randomized clinical trial. Eur Neurol 2016;76:28–34.

Wang Y, Meng R, Song H, et al. Remote ischemic conditioning may improve outcomes of patients with cerebral small-vessel disease. Stroke 2017;48:3064–72.

Liao Z, Bu Y, Li M, et al. Remote ischemic conditioning improves cognition in patients with subcortical ischemic vascular dementia. BMC Neurol 2019;19:206.

Ganesh A, Barber R, Black SE, et al. Trial of remote ischaemic preconditioning in vascular cognitive impairment (TRIC-VCI): protocol. BMJ Open 2020;10:e040466.

Zhao W, Li S, Ren C, et al. Chronic Remote Ischemic Conditioning May Mimic Regular Exercise: Perspective from Clinical Studies. Aging Dis 2018;9:165–71.

Wang C, Redgrave J, Shafizadeh M, et al. Aerobic exercise interventions reduce blood pressure in patients after stroke or transient ischaemic attack: a systematic review and meta-analysis. Br J Sports Med 2019;53:1515–25.

Alpuche J, Quirino L, Sánchez-Vega JT, et al. The role of platelets in ischemic conditioning. Card Med 2018;1:313–8.

Linden MD, Whittaker P, Frelinger AL, et al. Preconditioning ischemia attenuates molecular indices of platelet activation-aggregation. J Thromb Haemost 2006;4:2670–7.

Wang Y, Zhang Z, Zhang L, et al. RLIPostC protects against cerebral ischemia through improved synaptogenesis in rats. Brain Inj 2018;32:1429–36.

Esposito E, Desai R, Ji X. Pharmacologic pre- and postconditioning for stroke: basic mechanisms and translational opportunity. Brain Circulation 2015;1:104–13.

Koch S, Katsnelson M, Dong C, et al. Remote ischemic limb preconditioning after subarachnoid hemorrhage: a phase Ib study of safety and feasibility. Stroke 2011;42:1387–91.

Aronowski J, Zhao X. Molecular pathophysiology of cerebral hemorrhage. Stroke 2011;42:1781–8.
Supplementary material 1. Ongoing Studies of Remote Ischaemic Conditioning (RIC) in Stroke

| Study          | Status            | Population               | N   | RIC Protocol                  | Control Group(s)        | Primary Outcome                                           | Selected Secondary Outcome Measures                                      |
|----------------|-------------------|--------------------------|-----|-------------------------------|-------------------------|-----------------------------------------------------------|--------------------------------------------------------------------------|
| **REMOTE ISCHAEMIC PRE-CONDITIONING**          |                   |                          |     |                               |                         |                                                           |                                                                          |
| NEAT (NCT03496415) China 2018-19 | Recruiting        | Unruptured CA pre-ET    | 210 | Unspecified cycle length (200mmHg) | Sham RIC (60mmHg)       | New DWI lesions day 3                                       | Ischaemic lesion burden NIHSS day 7 mRS day 30                            |
| NCT03814850 USA 2019-22          | Not yet recruiting | Unruptured CA pre-ET    | 50  | 4 x 5 mins (30mmHg > SBP) Unilateral UL | Sham RIC (30mmHg)       | Adverse events                                            | Cognitive impairment day 2-4 and 9 months Ischaemic lesion volume day 2-4 |
| RIPAT (NCT02162654) Austria 2013-16 | Unknown            | Unruptured CA pre-ET/surgery | 48  | 3 x 5 mins (200mmHg) Unilateral UL | Sham RIC (10mmHg)       | Biomarkers (S100B, NSE, GFAP, MMP9, Microparticles)        | New ischaemic lesions day 1-2 NIHSS and mRS at 12 months                  |
| **REMOTE ISCHAEMIC PER-CONDITIONING AND/OR EARLY REMOTE ISCHAEMIC POST-CONDITIONING** |                   |                          |     |                               |                         |                                                           |                                                                          |
| RESCUE-BRAIN (NCT02189928) France 2015-19 | Completed          | AIS                      | 200 | 4 x 5 mins (110mmHg > SBP) Unilateral LL | Usual medical therapy   | DWI MRI infarct volume at 24 hrs                          | mRS day 90                                                               |
| Study | Recruitment status | Diagnosis | Duration | Treatment | Outcomes | Notes |
|-------|---------------------|-----------|----------|-----------|----------|-------|
| RICAMIS (NCT03740971) | Recruiting | AIS (NIHSS 6-16) | 180 days | 5 x 5 mins (200mmHg) Bilateral UL Twice daily 10-14 days | Usual care | mRS day 90 |
| RESIST (NCT03481777) | Recruiting | AIS and ICH | 150 days | 5 x 5 mins (200mmHg) Unilateral UL Twice daily up to 7 days | Sham RIC (20mmHg) | mRS day 90 |
| PROTECT-I (NCT03915782) | Not yet recruiting | AIS + MT | 126 days | 4 x 5 mins (200mmHg) UL | Sham RIC (30mmHg) | Infarct volume day 1 (FLAIR) |
| SERIC-sICH (NCT03484936) | Not yet recruiting | Acute sICH | 530 days | 4 x 5 mins (200mmHg) UL Twice daily 7 days | Sham RIC | mRS day 90 |
| REVISE-2 (NCT03045055) | Not yet recruiting | AIS + MT | 180 days | 4 x 5 mins (200mmHg) Unilateral UL | Sham RIC (60mmHg) | Final CT infarct volume |
| REPOST (NTR6880) | Recruiting | AIS | 200 days | 4 x 5 mins (20mmHg > SBP) Unilateral UL Twice daily up to 4 days | Sham RIC (50mmHg) | MRI DWI infarct volume day 4 (or day of discharge) |
| RICH | Recruiting | Acute sICH | 40 days | 4 x 5 mins | Usual Care | Adverse events |
| Study | Country | Phase | Intervention | Duration | Treatment | Primary Outcome | Additional Outcomes |
|-------|---------|-------|--------------|----------|------------|-----------------|---------------------|
| REMOTE-CAT (NCT03375762) | Spain | Recruiting | Suspected AIS | 572 | 5 x 5 mins Unspecified cuff pressure Non-paretic UL | Sham RIC (unspecified pressure) | mRS day 90 Early NIHSS change Infarct volume (DWI MRI) Metabolomic and lipidomic biomarkers |
| SERIC-AIS (NCT03669653) | China | Recruiting | AIS | 912 | 4 x 5 mins (200mmHg) UL Twice daily Up to 7 days | Sham RIC (60mmHg) | mRS day 90 NIHSS day 7 Inflammatory cytokines |
| SERICT-AIS (NCT04027621) | China | Completed | AIS + tPA | 50 | 4 x 5 mins (200mmHg) UL Twice between 6-24hrs post tPA | Sham RIC (60mmHg) | Adverse events NIHSS day 7 or discharge mRS day 90 |
| rTPA-RIC (NCT02886390) | China | Recruiting | AIS + tPA | 60 | 5 x 5 mins (200mmHg) Bilateral UL | tPA alone | MRI DWI infarct volume at 72 hours NIHSS day 5-7 mRS day 90 Recurrent events day 90 MMP-9, IL-6, HS-CRP at baseline and Day 7 |
| rTPA-RIC1 (NCT03231384) | China | Completed | AIS + tPA | 31 | 5 x 5 mins (200mmHg) Bilateral UL | tPA alone | Feasibility Signs of tissue or neurovascular injury Infarct volume (MRI) day 7 NIHSS day 7 mRS day 90 |
| RIC-ACS (NCT03868007) | China | Not yet recruiting | Age ≥ 60 AIS + ACS | 80 | 5 x 5 mins (200mmHg) | Sham RIC (60mmHg) | All cause mortality at 3 months NIHSS day 90 GRACE score day 90 |
| China 2019 | Recruiting | AIS + tPA | 120 | 5 x 5 mins (3 min deflations) (Unspecified cuff pressure) | Usual care | VEGF, bFGF up to 12 months | NIHSS day 14 | ADLs day 90 |
|-------|------------|----------|-----|--------------------------------------------------------|------------|-----------------------------|-------------|-------------|
| RIC-SIID (NCT04069546) China 2019-20 | Recruiting | AIS | 30 | 5 x 5 mins (180mmHg) Unilateral UL | Usual care | Flow cytometry (immune profile) | Serum cytokines at baseline, day 2 and day 7 (TLR-2, IL-6) Stroke associated pneumonia |
| ICARUS (NCT03481205) USA 2018-21 | Not yet recruiting | AIS & LVO (helicopter transit) | 10 | 3-5 x 5 mins (200mmHg) Bilateral UL | Usual care | Feasibility | Adverse events |
| NCT03335111 China 2016-19 | Recruiting | AIS | 100 | 5 x 5 mins (50mmHg > SBP) Bilateral UL for 7 days | Sham RIC (60mmHg) | Serum cytokines and peripheral immune cells at baseline, day 1 & day 7. | NIHSS day 7 Recurrent stroke at 12 months |
| ChiCTR-1800018290 China 2019-20 | Recruiting | AIS & SAH & ‘Brain-Heart Syndrome’ | 60 | Not specified | Usual care | Cardiac function (ECG, Echo, serum markers) | mRS at discharge, 30 days and 6 months |
| DIPIS (ChiCTR-IOR-17012011) China 2017-18 | Completed | AIS | 44 | Not specified | Sham RIC (unspecified pressure) | Stroke progression day 90 | mRS, NIHSS, vascular events and mortality day 90 |
| ChiCTR-IOR-1500654964 | Recruiting | AIS | 400 | 4 x 5 mins (200mmHg) | Sham RIC (30mmHg) | Feasibility | Infarct volume mRS |
| Location        | Country      | Study Period | Type of Intervention | Duration | Interventions | Adverse Events | Additional Biomarkers/Outcomes |
|-----------------|--------------|--------------|----------------------|----------|---------------|----------------|-------------------------------|
| China           |              | 2015-18      | Non-paretic UL       | 14 days  |               | NIHSS Mortality |                               |
| NCT03968068     | UK           | 2019-20      | AIS                  | 48       | 4 x 5 mins (200mmHg) Unilateral UL | 30 mins AE Discomfort (Likert Scale) % interventions completed | CBFv (TCD) |
| ERVAS           | India        | 2018-present | Aneurysmal SAH       | 24       | 3 x 5 mins (30mmHg > SBP) UL Every 48 hours up to day 7-10 | Sham RIC (30mmHg) | Vasospasm (TCD, angiography) Serum Biomarkers (S100B, NSE) GOSE at 1, 3 and 6 months |
| PreLIMBS        | USA          | 2018-22      | Aneurysmal SAH       | 60       | 3 x 10 mins (5 min deflation) (200mmHg) Unilateral LL every 1-2 days for 14 days | Sham RIC (30mmHg) | Adverse events mRS day 90 |
| NEAT2           | China        | 2018-19      | Ruptured CA + ET     | 210      | Unspecified cycles (200mmHg) Bilateral UL | Sham RIC (60mmHg) | Ischaemic lesions (MRI DWI) at 72 hours NIHSS day 7 Cerebrovascular events day 30 |

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s).
| Study | Design | Recruitment Status | Disease | Treatment | Outcomes |
|-------|--------|-------------------|---------|-----------|----------|
| RIPC-SAH (NCT02381522) USA 2015-19 | Active, not recruiting | Aneurysmal SAH | 26 cycles (unspecified length) (20mmHg > SBP) Unilateral LL | Sham RIC (20mmHg < SBP) | Vasospasm (TCD) mRS Mortality Additional neurological events |
| RICE-PAC (NCT03152799) UK 2017-19 | Unknown | AIS (anterior circulation) + MT | Unspecified protocol Non-parietal UL | Sham RIC | Penumbral salvage (MRI) at 3 months Cerebral oedema and infarct size day 7 mRS, NIHSS and QoL at 3 months |
| ChiCTR-INR-17012308 China 2017-20 | Not yet recruiting | AIS | 3 x 5 mins (20mmHg > SBP) Unilateral UL | Sham RIC (0mmHg) | Coagulant Function (TEG-MA) mRS at 12 months Recurrent ischaemic stroke |
| PICNIC-One (NCT03004820) 66 China 2016-17 | Completed | NDS or high-risk TIA | 5 x 5 min (200mmHg) Bilateral UL Twice daily 90 days | No comparator | Recurrent stroke/TIA day 90 Compliance Adverse events Handgrip strength in affected arm at day 90 NIHSS, mRS and BI day 90 |
| NCT03635177 Denmark 2019-21 | Recruiting | Lacunar stroke | Crossover: 4 x 5 mins (200mmHg) Unilateral UL Once daily 4 weeks | Crossover: Sham RIC | FMD (brachial artery) Femoral artery blood flow before and after exercise CBFv during visual task Platelet reactivity |
| EPIC-sICAS (NCT02323425) China 2015-18 | Unknown | sIntraCAS | 5 x 3 mins (5 mins deflation) (180mmHg) Bilateral UL | Usual care | Collateral circulation at 6 months (MRA, DCE-MRI, TCD, SPECT) NIHSS at 1 year VEGF and bFGF day 10 |
| NCT Number       | Status       | Diagnosis                                                                 | Time Points | Interventions                                                                                                                     | Outcomes                                                                                           |
|-----------------|--------------|---------------------------------------------------------------------------|-------------|----------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| NCT04039399     | Recruiting   | Chronic unilateral stroke with residual lower limb paresis               | Twice daily | Crossover: 5 x 5 mins (225mmHg) Unilateral LL (Paretic Leg)                                                                       | Cold Pressor Test and plasma epinephrine & norepinephrine SBP after RIC and cold pressor test       |
| USA 2019-20     |              |                                                                           | 180 days    | Crossover: Sham RIC (10mmHg)                                                                                                     |                                                                                                   |
| NCT04038697     | Recruiting   | Chronic unilateral cortical stroke with residual lower limb paresis      | Twice daily | 5 x 5 mins (225mmHg) Unilateral LL (Paretic Leg) 12 sessions over 4 weeks + Treadmill Training RIC alone RIC + Treadmill Training (healthy controls) | Self-selected walking speed at 4 weeks (10MWT) Knee extensor strength FMD of non-paretic brachial artery Heart rate variability |
| USA 2018-24     |              |                                                                           | 120         |                                                                                                                                  |                                                                                                   |
| NCT02534545     | Recruiting   | Ischaemic stroke or high-risk TIA                                         | Twice daily | 5 x 5 mins (200mmHg) Bilateral UL Once daily 12 months                                                                       | Time to recurrent stroke All cause mortality NIHSS, mRS and BI at 12 months                          |
| China 2015-19   |              |                                                                           | 300         | Sham RIC (60mmHg)                                                                                                               |                                                                                                   |
| RICFAST         | Recruiting   | Stroke at least 6 weeks prior with disabling fatigue                     | Twice daily | 4 x 5 mins (200mmHg) Unilateral UL 18 sessions over 6 weeks                                                                     | Feasibility Adverse events FSS 6 weeks Cerebral Perfusion (MRI Perfusion)                           |
| (NCT03794947)   |              |                                                                           | 34          | Sham RIC (20 mmHg)                                                                                                              |                                                                                                   |
| UK 2019-21      |              |                                                                           |             |                                                                                                                                  |                                                                                                   |
| ChiCTR-          | Recruiting   | sIntraCAS                                                                 | Twice daily | 5 x 5 min 3 x 3 min                                                                                                             | Recurrent stroke/TIA at NIHSS, mRS and BI at 12                                                  |
| Trial ID       | Country | Status          | Intervention | Study Details                                                                 | Control | Endpoint(s)                                                                 |
|---------------|---------|-----------------|--------------|-------------------------------------------------------------------------------|---------|-----------------------------------------------------------------------------|
| 1800014403    | China   | 2018-20         | (200mmHg)    | Bilateral UL, Twice daily, 12 months                                          |         | (200mmHg) Bilateral UL, Twice daily, 12 months                               |
|               |         |                 |              | Usual Treatment                                                               |         |                                                                             |
| NCT035890     | China   | 2018-19         | sIntraCAS    | 5 x 5 mins (200mmHg) Bilateral UL, Twice daily, 90 days                       | Sham RIC| CBF and brain metabolism under stress                                         |
| PICASSO       | USA     | Completed       | sIntraCAS    | 4 x 5 mins (200mmHg) Bilateral UL, Daily 30 days                              | Usual care| CBF (MRI ASL) day 30                                                          |
|               |         |                 |              |                                                                             |         | Feasibility                                                                  |
|               |         |                 |              |                                                                             |         | Biomarkers at day 30 (including Nitrite, IL-10, hs-CRP and MMP-9)             |
| REM-PROTECT   | USA     | Recruiting      | ≥40 yrs      | 4 x 5 mins (Unspecified cuff pressure) Bilateral UL, Once or twice daily, One year| Usual care| Adherence                                                                   |
|               |         |                 | Lacunar stroke|                                                                             |        | Patient-reported discomfort                                                  |
| NCT03105141   | China   | Recruiting      | sIntraCAS    | 60 Bilateral UL, 10 treatment groups with varied number of cycles, cycle lengths, frequency and cuff pressure| Several active comparators| Recurrent stroke at 12 months                                                |
|               |         |                 |              |                                                                             |        | Adverse events                                                               |
|               |         |                 |              |                                                                             |        | Cerebral perfusion (multi-modal)                                             |
|               |         |                 |              |                                                                             |        | Cognition (MMSE, MOCA, TICS-M)                                               |
| ChiCTR190002  | Not yet | sIntraCAS       | Not specified| Sham RIC                                                                     | NIHSS, mRS & BI day | Vascular events day 180                                                      |

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance on the data or information contained in this supplement which has been supplied by the author(s).
| Study Code               | Status             | Intervention Details                                                                 | Duration | Endpoint Measures                                              |
|-------------------------|--------------------|---------------------------------------------------------------------------------------|----------|-----------------------------------------------------------------|
| 1006                    | China 2019         | recruiting                                                                             |          | (unspecified pressure)                                          | 180      | CBF at day 180                                                   |
| RIC-CCCA (NCT03721692)  | China 2018-24      | Enrolling by Invitation sIntraCAS & sCAS                                               | 392      | 5 x 5 mins (Unspecified cuff pressure) UL                       | Usual care | Combined vascular events at 1 year                              | Time to vascular event All cause mortality at 1 year mRS day 90 |
| NCT02971462             | China 2016-17      | Unknown sIntraCAS                                                                      | 80       | 5 x 5 mins (200mmHg) Bilateral UL                               | Usual care | Posterior circulation stroke at 6 months                      | Combined cerebrovascular events at 6 months mRS at 6 months CBF (TCD) at 6 months |
| ChiCTR-OPC-17012871     | China 2016-18      | Unknown Ischaemic stroke                                                               | 50       | Daily RIC (not further specified)                               | None      | Depression incidence                                           | HDS                                                              |
| UNDETERMINED            |                    |                                                                                       |          |                                                                 |          |                                                                 |                                                                  |
| ChiCTR-1900026034       | China 2018-21      | Recruiting AIS                                                                         | 104      | Not specified                                                   | Usual care | Neuropsychological evaluation P300 event-related potential ICAM-1 Endothelin-1 |

**Key:**
10MWT – 10 meter walk test
ACS – Acute Coronary Syndrome
ADL – Activities of daily living
AE – Aerobic exercise
AIS – Acute Ischaemic Stroke
AIS + MT – Acute Ischaemic Stroke plus Mechanical Thrombectomy
ASL – Arterial spin-labeled
BDNF – Brain-derived neurotrophic factor
BI – Barthel index
bFGF – Basic Fibroblast Growth Factor
CA – Cerebral aneurysm
CBF(v) – Cerebral blood flow (velocity)
DCE-MRI – Dynamic Contrast-Enhanced Magnetic Resonance Imaging
DWI – Diffusion Weighted Imaging
ET – Endovascular Therapy
FMD – Flow Mediated Dilatation
FSS – Fatigue Severity Score
GOSE – Extended Glasgow Outcome Scale
GFAP – Glial Fibrillary Acidic Protein
HDS – Hamilton Depression Scale
HIF-1α – Hypoxia-inducible Factor 1-Alpha
HSP – Heat shock proteins
HS-CRP – High Sensitivity C reactive Protein
ICAM-1 – Intracellular Adhesion Molecule 1
ICH – Intracerebral Haemorrhage
IL-1β – Interleukin 1 Beta
IL-4 – Interleukin 4
IL-6 – Interleukin 6
IL-10 – Interleukin 10
LL – Lower Limb
LVO – Large Vessel Occlusion
MMP-9 – Matrix metalloproteinase-9
MFI – Multidimensional Fatigue Inventory
MMSE – Mini-Mental State Examination
MOCA – Montreal Cognitive Assessment
mRS – Modified Rankin Scale
NDS – Non-disabling Stroke
NIHSS – National Institutes of Health Stroke Scale
NSE – Neuron-Specific Enolase
QoL – Quality of Life Assessment
S100B – S100 calcium-binding protein B
SAH – Subarachnoid Haemorrhage
SBP – Systolic Blood Pressure
sIntraCAS – Symptomatic Intracranial Atherosclerosis
sCAS – Symptomatic Coronary Artery Stenosis
SPECT – Single Photon Emission Computed Tomography
TCD – Transcranial Doppler
TEG-MA – Thromboelastography
TIA – Transient Ischaemic Attack
TICS-M – Modified Telephone Interview for Cognitive Status
TLR-2 – Toll-like Receptor 2
TNFα – Tumour Necrosis Factor Alpha
tPA – Tissue Plasminogen Activator (Intravenous Thrombolysis)
UL – Upper Limb
VEGF – Vascular Endothelial Growth Factor

62. Li X-Q, Tao L, Zhou Z-H et al. Remote ischemic conditioning for acute moderate ischemic stroke (ricamis): Rationale and design. International Journal of Stroke. 0:1747493019879651
63. Landman T, Schoon Y, Warlé M et al. The effect of repeated remote ischemic postconditioning on infarct size in patients with an ischemic stroke (repost): Study protocol for a randomized clinical trial. Trials. 2019;20:167
64. Li Y, Liang K, Zhang L et al. Upper limb ischemic postconditioning as adjunct therapy in acute stroke patients: A randomized pilot. Journal of Stroke and Cerebrovascular Diseases. 2018;27:3328-3335
65. Sangeetha RP, Ramesh VJ, Kamath S et al. Effect of remote ischemic preconditioning on cerebral vasospasm and biomarkers of cerebral ischemia in aneurysmal subarachnoid hemorrhage (ervas): A protocol for a randomized, controlled pilot trial. Brain circulation. 2019;5:12-18
66. Liu SM, Zhao WL, Song HQ et al. Rationale and study design for a single-arm phase iia study investigating feasibility of preventing ischemic cerebrovascular events in high-risk patients with acute non-disabling ischemic cerebrovascular events using remote ischemic conditioning. Chinese Med J-Peking. 2018;131:347-351
**Supplementary material 2.** Serum biomarkers under investigation as mechanistic markers of the effects of Remote Ischaemic Conditioning in Stroke.

| Serum Biomarker | Study |
|-----------------|-------|
| S100B           | RIPAT (NCT02162654)²⁶, ERVAS³⁸ |
| NSE             | RIPAT (NCT02162654)²⁶, ERVAS³⁸ |
| GFAP            | RIPAT (NCT02162654)³⁵ |
| MMP-9           | RIPAT (NCT02162654)²⁶, rTPA-RIC (NCT02886390), PICASSO (NCT03208166) |
| BDNF            | RICAMIS (NCT03740971)³⁵ |
| VEGF            | RICAMIS (NCT03740971)³⁵, TRIPCAIS (NCT03218293), EPIC-sICAS (NCT02323425). |
| HIF-1α          | RICAMIS (NCT03740971)³⁵ |
| TNF-α           | RICAMIS (NCT03740971)³⁵ |
| IL-1β           | RICAMIS (NCT03740971)³⁵ |
| IL-4            | RICAMIS (NCT03740971)³⁵ |
| IL-6            | RICAMIS (NCT03740971)³⁵, rTPA-RIC (NCT02886390), RIC-SIID (NCT04069546) |
| IL-10           | PICASSO (NCT03208166) |
| TLR-2           | RIC-SIID (NCT04069546) |
| MicroRNA        | RESIST (NCT03481777) |
| HS-CRP          | rTPA-RIC (NCT02886390), PICASSO (NCT03208166) |
| bFGF            | TRIPCAIS (NCT03218293), EPIC-sICAS (NCT02323425) |
| TEG-MA          | ChiCTR-INR-17012308 |
| Platelet reactivity | NCT03635177 |
| Epinephrine     | NCT04039399 |
| Norepinephrine  | NCT04039399 |
| Nitrite         | PICASSO (NCT03208166) |
| ICAM-1          | ChiCTR-1900026034 |
| Endothelin-1    | ChiCTR-1900026034 |

S100B – S100 calcium-binding protein B  
NSE – Neuron-Specific Enolase  
GFAP – Glial Fibrillary Acidic Protein  
MMP-9 – Matrix metalloproteinase-9  
BDNF – Brain-derived neurotrophic factor  
VEGF – Vascular Endothelial Growth Factor  
HIF-1α – Hypoxia-inducible Factor 1-Alpha  
TNFα – Tumour Necrosis Factor Alpha  
IL-1β – Interleukin 1 Beta  
IL-4 – Interleukin 4  
IL-6 – Interleukin 6  
IL-10 – Interleukin 10
TLR-2 – Toll-like Receptor 2
HS-CRP – High Sensitivity C Reactive Protein
bFGF – Basic Fibroblast Growth Factor
TEG-MA – Thromboelastography
ICAM-1 – Intracellular Adhesion Molecule 1